The Significance of Bayesian Pharmacokinetics in Dosing for Critically Ill Patients: A Primer for Clinicians Using Vancomycin as an Example
- PMID: 37760737
- PMCID: PMC10525617
- DOI: 10.3390/antibiotics12091441
The Significance of Bayesian Pharmacokinetics in Dosing for Critically Ill Patients: A Primer for Clinicians Using Vancomycin as an Example
Abstract
Antibiotic use is becoming increasingly challenging with the emergence of multidrug-resistant organisms. Pharmacokinetic (PK) alterations result from complex pathophysiologic changes in some patient populations, particularly those with critical illness. Therefore, antibiotic dose individualization in such populations is warranted. Recently, there have been advances in dose optimization strategies to improve the utilization of existing antibiotics. Bayesian-based dosing is one of the novel approaches that could help clinicians achieve target concentrations in a greater percentage of their patients earlier during therapy. This review summarizes the advantages and disadvantages of current approaches to antibiotic dosing, with a focus on critically ill patients, and discusses the use of Bayesian methods to optimize vancomycin dosing. The Bayesian method of antibiotic dosing was developed to provide more precise predictions of drug concentrations and target achievement early in therapy. It has benefits such as the incorporation of personalized PK/PD parameters, improved predictive abilities, and improved patient outcomes. Recent vancomycin dosing guidelines emphasize the importance of using the Bayesian method. The Bayesian method is able to achieve appropriate antibiotic dosing prior to the patient reaching the steady state, allowing the patient to receive the right drug at the right dose earlier in therapy.
Keywords: Bayesian statistics; critically ill patient; intensive care units; personalized medicine; therapeutic drug monitoring; vancomycin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Using Electronic Health Records for Personalized Dosing of Intravenous Vancomycin in Critically Ill Neonates: Model and Web-Based Interface Development Study.JMIR Med Inform. 2022 Jan 31;10(1):e29458. doi: 10.2196/29458. JMIR Med Inform. 2022. PMID: 35099393 Free PMC article.
-
Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.Am J Health Syst Pharm. 2020 Jul 7;77(14):1104-1112. doi: 10.1093/ajhp/zxaa128. Am J Health Syst Pharm. 2020. PMID: 32537644 Review.
-
Optimization of dosing regimens and dosing in special populations.Clin Microbiol Infect. 2015 Oct;21(10):886-93. doi: 10.1016/j.cmi.2015.05.002. Epub 2015 May 14. Clin Microbiol Infect. 2015. PMID: 25980350 Review.
-
First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.Pharmacotherapy. 2020 Dec;40(12):1210-1218. doi: 10.1002/phar.2486. Epub 2020 Dec 11. Pharmacotherapy. 2020. PMID: 33176005
-
Optimization of antimicrobial therapy in critically ill patients, What Clinicians and Searchers Must Know.Anaesth Crit Care Pain Med. 2025 May 27:101561. doi: 10.1016/j.accpm.2025.101561. Online ahead of print. Anaesth Crit Care Pain Med. 2025. PMID: 40441484 Review.
Cited by
-
At the Intersection of Critical Care and Infectious Diseases: The Year in Review.Biomedicines. 2024 Mar 2;12(3):562. doi: 10.3390/biomedicines12030562. Biomedicines. 2024. PMID: 38540175 Free PMC article. Review.
-
Advances in Psychotropic Treatment for Pregnant Women: Efficacy, Adverse Outcomes, and Therapeutic Monitoring.J Clin Med. 2024 Jul 27;13(15):4398. doi: 10.3390/jcm13154398. J Clin Med. 2024. PMID: 39124665 Free PMC article. Review.
-
Individualization of piperacillin dosage based on therapeutic drug monitoring with or without model-informed precision dosing: a scenario analysis.J Antimicrob Chemother. 2025 Mar 3;80(3):840-847. doi: 10.1093/jac/dkaf007. J Antimicrob Chemother. 2025. PMID: 39821648 Free PMC article.
References
-
- Magiorakos A.P., Srinivasan A., Carey R., Carmeli Y., Falagas M., Giske C., Harbarth S., Hindler J., Kahlmeter G., Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources